Neurogene Therapeutics (NGNE) - Kapitalizatsiyaning foydaga nisbati
Neurogene Inc. (NGNE) qimmatqimmatlarining bozor dinamikasi -4.30 ko'rsatkichini namoyish etmoqda. Neurogene Inc. (NGNE) New-York va Texasdagi o'z markazlariga tayanadi, bu esa gen terapiyalarini ishlab chiqishda barqarorlikni ta'minlaydi. Avtomatlashtirilgan tizimlarning joriy etilishi ommaviy skrining orqali samarali vektorlarni qidirishni tezlashtiradi. Shu bilan birga, kapital xarajatlarni minimallashtirish uchun ishlab chiqarish va sinovlarni tashqi pudratchilarga topshirish orqali tarkibiy moslashuvchanlik saqlanib qolingan.
Neurogene Corp (NGNE) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil
- joriy narx va aksiyalarning prognoz qilingan qiymati:
- bozor kapitallashuvi ko'rsatkichlari:
- xususiy kapitalning balans qiymati ko'rsatkichlari:
- qarz majburiyatlari va likvidlik statistikasi:
Qarzning kapitalga nisbati Neurogene Inc.|NGNE - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli qarzdorlikning o'z kapitaliga nisbati Neurogene Therapeutics|NGNE - Kompaniyaning jamlangan qarzlari|Balans qiymatiga qarzlar Neurogene Inc.|NGNE - Kompaniyaning uzoq muddatli qarzi|Kompaniyaning qisqa muddatli qarzdorligi Neurogene|Shoshilinch likvidlik neurogene.com
- sof foyda va baholash koeffitsiyentlari ma'lumotlari:
NGNE - Sof daromad|Kutilayotgan sof daromad Neurogene Inc.|NGNE - P/E multiplikatori|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Neurogene Inc|NGNE - Narxning foydaga va o‘sish sur’atiga nisbati|Korxona qiymatining amortizatsiyadan oldingi operatsion foydaga nisbati Neurogene Inc.|NGNE - EBITDA operatsion foydasi|So'nggi 12 oy davomida bir aksiya uchun sof foyda Neurogene|NGNE - So'nggi 12 oy davomida bir aksiya uchun sof foyda|So'nggi o'n ikki oy davomida bir aksiya uchun sof foydaning yillik o'zgarishi neurogene.com|NGNE - Joriy yilda bir aksiya uchun foyda o'sishi|Keyingi yil uchun bir aksiya uchun foydaning prognoz qilingan o'sish sur'ati Neurogene Inc.
Kompaniyaning jamlanma tahlili:NGNE (neurogene.com)
Neurogene Inc. (NGNE) aktivlarining sifatini baholash uchun foyda va narx koeffitsiyenti (P/E) tahlili talab etiladi. Kompaniyaning o'tgan davrdagi P/E koeffitsiyenti joriy foydaga nisbatan investitsiyalar rentabelligiga bo'lgan bozor kutuvlarini aks ettiradi. Ushbu gen terapiyasi ishlab chiquvchisi uchun mazkur ko'rsatkich Rett sindromini davolashdagi kuchli obro'si tufayli belgilangan premiumni o'lchaydi. Ushbu metrikaning monitoringi biznesning haddan tashqari qimmat baholanganini yoki kapitalning yetarlicha baholanmagan salohiyatini o'z vaqtida aniqlash imkonini beradi.
Raqobatdosh kompaniyalar tahlili
Narx-foyda multiplikatori BIIB (biogen.com)|P/E multiplikatori NBIX|RGC - Kapitalizatsiyaning foydaga nisbati|Axsome Therapeutics Inc - Narx-foyda koeffitsiyenti|P/E multiplikatori ACADIA Corp ACAD|XENE - Narxning foydaga nisbati|Kompaniya qiymatining sof foydaga nisbati VKTX (vikingtherapeutics.com)|Supernus (SUPN) - Narxning foydaga nisbati|Kapitalizatsiyaning foydaga nisbati Catalyst Pharma (CPRX)|DNLI (Denali Therapeutics Inc) - P/E multiplikatori|HRMY - Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti|P/E multiplikatori BHVN|AMLX - Kapitalizatsiyaning foydaga nisbati|Narxning foydaga nisbati Trevi Therapeutics, Inc. TRVI|PRAX: Narx-foyda multiplikatori|Anavex Corp - P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati CeriBell EEG|PRTA (prothena.com) - Narx-foyda koeffitsiyenti|Alector - Kompaniya qiymatining sof foydaga nisbati|ANNX (Annexon) - P/E multiplikatori|Omeros Corp. (OMER) - Biznesning o‘zini qoplash muddati|Narxning foydaga nisbati AC Immune Corp (ACIU)|Voyager Corp - Narx-foyda multiplikatori|P/E multiplikatori NMRA (Neumora Therapeutics)|SCLX - Narx-foyda koeffitsiyenti|TVGN: Narx-foyda koeffitsiyenti|Biznesning o‘zini qoplash muddati Alpha Cognition ACOG|Cognition Therapeutics, Inc. (CGTX) - Narxning foydaga nisbati|Narx-foyda multiplikatori IKT|SAVA (Cassava Sciences, Inc.) - P/E multiplikatori|ASRT - Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti|Narxning foydaga nisbati Coya Therapeutics, Inc. (COYA)|vistagen.com - Narx-foyda multiplikatori|P/E multiplikatori OVID (Ovid Therapeutics)|Acumen Pharmaceuticals, Inc (ABOS) - Kapitalizatsiyaning foydaga nisbati|CRVO - Narxning foydaga nisbati|ATHE (Alterity Therapeutics) - Narx-foyda multiplikatori|CLNN: P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati PepGen (PEPG)|Narx-foyda koeffitsiyenti JUNS|P/E multiplikatori Relmada Corp|Narxning foydaga nisbati Annovis Bio, Inc. (ANVS)|GRCE (gracetx.com) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Firefly Neuroscience AIFF|ANEW Medical (KLTO) - Kapitalizatsiyaning foydaga nisbati|NRSN - Narxning foydaga nisbati|RVPH (Reviva Pharmaceuticals, Inc.) - Narx-foyda multiplikatori|MTVA: P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati neuraxis.com (NRXS)|Narx-foyda koeffitsiyenti HSDT|P/E multiplikatori Passage Bio Corp|Narxning foydaga nisbati Neuphoria Therapeutics Inc. (NEUP)|NERV (Minerva) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Athira Pharma, Inc. ATHA|addextherapeutics.com (ADXN) - Kapitalizatsiyaning foydaga nisbati|Alzamend - P/E multiplikatori|Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti Cyclerion Therapeutics (CYCN)|PTIX: P/E multiplikatori|Kapitalizatsiyaning foydaga nisbati Pasithea Therapeutics Corp. (KTTA)|Narxning foydaga nisbati Cortigent Inc|Narx-foyda multiplikatori ATXI (avenuetx.com)|P/E multiplikatori BCLI|CARA - Kapitalizatsiyaning foydaga nisbati|Chromocell Therapeutics Corporation - Narx-foyda koeffitsiyenti|Kompaniya qiymatining sof foydaga nisbati ELYM|Intra-Cellular - P/E multiplikatori|Biznesning o‘zini qoplash muddati longboardpharma.com LBPH|Marinus Pharmaceuticals, Inc. (MRNS) - Narxning foydaga nisbati|Narx-foyda multiplikatori NKGN|NRBO (NeuroBo) - P/E multiplikatori|Narx-foyda koeffitsiyenti Sage Therapeutics Inc (SAGE)|Narx-foyda koeffitsiyenti SNPX (Synaptogenix, Inc.)|Biznesning o‘zini qoplash muddati trevena.com|Narxning foydaga nisbati Vigil Neuroscience, Inc. VIGL|WENA: Narx-foyda multiplikatori|Cerevel - P/E multiplikatori
